Angiotensin II receptor antagonists: Where do we stand?

IDrugs

Volumn 3, Issue 3, 2000, Pages 304-309

  Burnier, Michel ^a   Maillard, Marc ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000147017     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Houghton AR, Cowley AJ: Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? Int J Cardiol (1997) 59:7-10.
2. Wexler RR, Greenlee WJ, Irivin JD, Goldberg MR, Prendergast K, Smith RD, Timmermans PBMWM: Nonpeptide angiotensin II receptor antagonists: The next generation in antihypertensive therapy. J Med Chem (1996) 39(3):625-656.
3. Smith RD, Timmermans PBMWM: Human angiotensin receptor subtypes. Curr Opin Nephrol Hypertens (1994) 3:112-122.
4. Bergsma DJ, Ellis C, Kumar C, Nuthulaganti P, Kersten H, Elshourbagy N, Griffin E, Stadel JM, Alyar N: Cloning and characterization of a human angiotensin II type 1 receptor. Biochem Biophys Res Commun (1992) 183:989-995.
5. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T: Molecular cloning of a novel angiotensin it receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem (1993) 268:24543-24546.
6. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ: Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem (1993) 68:24539-24542.
7. 2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase. Biochem Biophys Res Commun (1992) 183(1):206-211.
8. 1 receptor: Gain-of-function study using gene transfer. Proc Natl Acad Sci USA (1995) 92:10663-10667.
9. 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest (1995) 95:651-657.
10. 2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol (1996) 1222:59-67.
11. Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, Maruyama K, Masaki H, Tsutumi Y, Shibazaki Y, Iwasaka T, Inada M: Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation (1997) 96:3954-3962.
12. 2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension (1998) 31:349-355.
13. 2) receptor. Curr Hypertension Rep (1999) 1(2):151-157.
14. Johnston CI: Angiotensin receptor antagonist: Focus on losartan. Lancet (1995) 346:1403-1407.
15. Chiolero A, Burnier M: Pharmacology of valsartan, an angiotensin II receptor antagonist. Exp Opin Invest Drugs (1998) 7(11):1915-1925.
16. Gillis JC, Markham A: Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs (1997) 54(6):885-902.
17. Sever P: Candesartan cilexetil: A new, long-acting, effective angiotensin II type 1 receptor blocker. J Hum Hypertens (1997) 11(Suppl 2):S91-S95.
18. McClellan KJ, Markham A: Telmisartan. Drugs (1998) 56(6):1039-1044.
19. McClellan KJ, Balfour JA: Eprosartan. Drugs (1998) 55(5):713-718.
20. Lacourcière Y, Brunner HR, Irwing R, Karlberg BE, Ramsay LE, Snavely DB, Dobbins TW, Faison EP, Nelson EB, and the Losartan Cough Study Group: Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens (1994) 12:1387-1393.
21. Benz J, Oshrain C, Henry D, Avery C, Chiang Y, Gatlin M: Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol (1997) 37(2):101-107.
22. Mazzolai L, Burnier M: Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf (1999) 21(1):23-33.
23. van Rijnsoever EW, Kwee-Zuiderwijk, WJ, Feenstra J: Angioneurotic edema attributed to the use of losartan. Arch Intern Med (1998) 158(18): 2063-2065.
24. 1-receptor blockers in hypertension and heart failure: Clinical experience and future directions. Eur Heart J (1999) 20:997-1008.
25. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in The Elderly study, ELITE). Lancet (1997) 349:747-752.
26. Anonymous: Phase I results of the randomized evaluation of left ventricular dysfunction (RESOLVD) trial. Am J Managed Care (1998) 4(7):S380-S383.
27. Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, Pauly N, Brunner HR: Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol (1990) 15:276-282.
28. Nussbeger J, Waeber B, Brunner HR: Clinical pharmacology of ACE inhibition. Cardiology (1989) 76 (Suppl 2):11-22.
29. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT study group. Lancet (1998) 351:1755-1762.
30. Nussberger J, Brunner DB, Waeber B, Brunner HR: True versus immunoreactive angiotensin II in human plasma. Hypertension (1985) 7(Suppl I):I1-I7.
31. Urata K, Kinoshita A, Misono K, Bumpus FM, Husain A: Identification of a highly specific chymase as the major angiotensin-forming enzyme in the human heart. J Biol Chem (1990) 265:22348-22382.
32. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, Maggon K, Shum L, Timmermans PBMWM, Brunner HR: Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation (1991) 83:1333-1342.
33. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Ménard J: Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation (1995) 92:825-834.
34. Hebert LA, Falkenheim ME, Nahman NS, Cosio FG, O'Dorisio TM: Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol (1999) 19(1):1-6.
35. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis (1999) 33(5):851-856.
36. Pitt B, Dickstein K, Benedict C et al. Combined treatment with losartan and enalapril vs enalapril on neurohormonal activation in patients with heart failure. Circulation (1996) 94:I-428.
37. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN: Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to an angiotensin Converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation (1999) 99(20):2658-2664.
38. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Olivari MT, Thomas S, Le Jemtel TH: Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation (1999) 99(8):990-992.
39. Ots M, MacKenzie HS, Troy JL, Rennke HG, Brenner BM: Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol (1998) 9:224-230.
40. 1 receptor antagonists. Hypertension (1999) 33(3):850-855.